Navellier & Associates Inc cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,416 shares of the company’s stock after selling 384 shares during the quarter. Navellier & Associates Inc’s holdings in Johnson & Johnson were worth $1,775,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in JNJ. OLD Point Trust & Financial Services N A boosted its position in Johnson & Johnson by 2.2% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after buying an additional 1,321 shares during the period. Lynch & Associates IN lifted its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares during the period. Welch & Forbes LLC lifted its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after purchasing an additional 6,730 shares during the period. Oakbrook Investments LLC lifted its position in shares of Johnson & Johnson by 7.4% in the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after purchasing an additional 9,375 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after purchasing an additional 3,533 shares during the period. 65.89% of the stock is currently owned by institutional investors.

A number of brokerages have recently issued reports on JNJ. Citigroup boosted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a research report on Monday, October 30th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets boosted their price target on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Finally, Leerink Swann restated an “outperform” rating and issued a $165.00 price target (up previously from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $145.04.

Shares of Johnson & Johnson (JNJ) opened at $142.46 on Friday. The company has a market cap of $382,721.66, a price-to-earnings ratio of 19.95, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a one year low of $110.76 and a one year high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.68 EPS. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

TRADEMARK VIOLATION NOTICE: “Navellier & Associates Inc Decreases Position in Johnson & Johnson (JNJ)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/17/navellier-associates-inc-decreases-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.